Damora Therapeutics (DMRA) Accounts Payables (2019 - 2026)
Damora Therapeutics (DMRA) reported Accounts Payables of $819000.0 for Q1 2026, up 131.36% on a YoY basis from $354000.0 in Q1 2025, and up 84.46% quarter-over-quarter from $444000.0 in Q4 2025.
Damora Therapeutics (DMRA) Accounts Payables (2019 - 2026) Analysis & Trends
Damora Therapeutics has reported Accounts Payables for 8 years, with the latest figure at $819000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 131.36% year-over-year to $819000.0; the trailing twelve-month figure through Mar 2026 stood at $819000.0 (up 131.36% YoY), and the FY2025 full-year result was $444000.0, up 17.77% from the prior year.
- Accounts Payables for Q1 2026 stood at $819000.0, up from $444000.0 in the prior quarter.
- The five-year high for Accounts Payables was $5.6 million in Q2 2023, with the low at $354000.0 in Q1 2025.
- Historically, Accounts Payables has averaged $1.9 million across 5 years, with a median of $1.7 million in 2024.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 134.77% — and 2024, when it plunged 88.76%.
- Damora Therapeutics' Accounts Payables stood at $3.4 million in 2022, then sank by 49.19% to $1.7 million in 2023, then slumped by 77.85% to $377000.0 in 2024, then grew by 17.77% to $444000.0 in 2025, then soared by 84.46% to $819000.0 in 2026.
- The last three Accounts Payables figures came in at $819000.0 (Q1 2026), $444000.0 (Q4 2025), and $520000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 8.64 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 34.55 Mn |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | 819,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 819,000.00 |
| Dec 31, 2025 | 444,000.00 |
| Sep 30, 2025 | 520,000.00 |
| Jun 30, 2025 | 756,000.00 |
| Mar 31, 2025 | 354,000.00 |
| Dec 31, 2024 | 377,000.00 |
| Sep 30, 2024 | 503,000.00 |
| Jun 30, 2024 | 724,000.00 |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 5.56 Mn |
| Mar 31, 2023 | 3.55 Mn |
| Dec 31, 2022 | 3.35 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 2.82 Mn |
| Mar 31, 2022 | 3.22 Mn |
| Dec 31, 2021 | 1.53 Mn |
| Sep 30, 2021 | 1.98 Mn |
| Jun 30, 2021 | 1.59 Mn |